Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 11—November 2022
CME ACTIVITY - Synopsis

Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia

Jonathan Li, Cindy Lau, Naomi Anderson, Fay Burrows, Feras Mirdad, Lilibeth Carlos, Andrew J. Pitman, Kavitha Muthiah, David R. Darley, David Andresen, Peter Macdonald, Deborah Marriott1, and Nila J. Dharan1Comments to Author 
Author affiliations: St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia (J. Li, C. Lau, N. Anderson, F. Burrows, F. Mirdad, L. Carlos, K. Muthiah, D.R. Darley, D. Andresen, P. Macdonald, D. Marriott, N.J. Dharan); Australian Research Council Centre of Excellence for Climate Extremes and Climate Change Research Centre, at UNSW Sydney, Sydney, New South Wales(A.J. Pitman); Victor Chang Cardiac Research Institute, Darlinghurst (K. Muthiah, P. Macdonald); UNSW Sydney, Sydney (D.R. Darley, N.J. Dharan); University of Notre Dame, Sydney (D. Andresen)

Main Article

Table 3

Comparison of the number and proportion of Nocardia isolates susceptible to select antimicrobial drugs between heart and lung transplant recipients, Greater Sydney, New South Wales, Australia, June 2015–March 2021*

Drug Heart transplant, n = 16 Lung transplant, n = 7 p value All patients, n = 23
Amikacin 16 (100) 7 (100) Referent 23 (100)
Augmentin 0 0/6 Referent 0/22 (0)
Cefepime 1/15 (6.7) 3/6 (50.0) 0.02 4/21 (19.0)
Ceftriaxone 3 (18.8) 4 (57.1) 0.07 7 (30.4)
Ciprofloxacin 4 (25.0) 1 (14.3) 0.57 5 (21.7)
Clarithromycin 10 (62.5) 4 (57.1) 0.81 14 (60.9)
Doxycycline 1/15 (6.7) 2 (28.6) 0.16 3/22 (13.6)
Imipenem 7 (43.8) 3 (42.9) 0.97 10 (43.5)
Linezolid 16 (100) 7 (100) Referent 23 (100)
Minocycline 1 (6.3) 2 (28.6) 0.14 3 (13.0)
Moxifloxacin 4 (25.0) 1/6 (16.7) 0.68 5/22 (22.7)
Tobramycin 4 (25.0) 2/6 (33.3) 0.70 6/22 (27.3)]
Sulfamethoxazole/trimethoprim 15 (93.8) 7 (100) 0.50 22 (95.7)

*Values are no. (%) patients except as indicated. Denominators are indicated for categories in which only some patients had data available.

Main Article

1These authors contributed equally to this article.

Page created: September 20, 2022
Page updated: October 21, 2022
Page reviewed: October 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external